10-K Decoder · All companies

Anika Therapeutics, Inc.

ANIK · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$113M$120M−5.9%
Operating income−$11.1M−$5.10M−117%
Net income−$10.9M−$56.4M+80.7%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 6, 2026

$Q3 2026Year earlierChange
Revenue$30.6M$27.8M+10.1%
Operating income−$700K−$3.20M+78.1%
Net income−$300K−$2.30M+87.0%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Anika Therapeutics's revenue in FY2025?
$113M in FY2025 (Fiscal year ended Dec 31, 2025), −5.9% vs $120M a year earlier, per its 10-K filed Mar 2026.
Was Anika Therapeutics profitable in FY2025?
No: net income was −$10.9M and operating income −$11.1M in FY2025.
What was Anika Therapeutics's revenue in Q3 2026?
$30.6M (+10.1% vs a year earlier), per its Form 10-Q filed Nov 6, 2026.